Eli Lilly and Company logo LLY - Eli Lilly and Company

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 33
HOLD 9
SELL 3
STRONG
SELL
0
| PRICE TARGET: $1,315.42 DETAILS
HIGH: $1,500.00
LOW: $1,135.00
MEDIAN: $1,300.00
CONSENSUS: $1,315.42
UPSIDE: 11.56%

About Eli Lilly and Company (https://www.lilly.com)

Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.

Key Executives

NAME TITLE DOB SALARY
David A. Ricks Chairman & CEO 1968 $8,921,701 USD
Daniel Skovronsky Chief Scientific & Product Officer and President of Lilly Research Laboratories 1974 $4,898,731 USD
Anat Hakim Executive Vice President, General Counsel & Secretary 1969 $3,342,570 USD
Lucas E. Montarce Executive Vice President & Chief Financial Officer 1977 $3,240,000 USD
Jacob S. Van Naarden Executive VP, President of Lilly Oncology & Head of Corporate Business Development 1985 $2,998,730 USD
Diogo Rau Executive VP and Chief Information & Digital Officer 1975 $1,056,809 USD
Donald A. Zakrowski Senior Vice President of Finance & Chief Accounting Officer
Eric Dozier Executive Vice President & Chief People Officer 1967
Ilya Yuffa Executive VP and President of Lilly USA & Global Customer Capabilities 1975
Michael Czapar Director of Investor Relations

Company Peers

Peer analysis pending, check back in 1-2 minutes.